Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: Response based on genotype.
Suzanne George
Consultant or Advisory Role - Bayer; GlaxoSmithKline
Research Funding - Bayer; Novartis; Pfizer
Yang Feng
No relevant relationships to disclose
Margaret von Mehren
No relevant relationships to disclose
Edwin Choy
Consultant or Advisory Role - Amgen
Christopher L. Corless
No relevant relationships to disclose
Jason L. Hornick
No relevant relationships to disclose
James E. Butrynski
No relevant relationships to disclose
Andrew J. Wagner
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - Novartis; Pfizer
Sarah Solomon
No relevant relationships to disclose
Jeffrey A. Morgan
No relevant relationships to disclose
Michael C. Heinrich
Consultant or Advisory Role - ARIAD; MolecularMD; Novartis; Pfizer
Stock Ownership - MolecularMD
Honoraria - Onyx (B)
Research Funding - ARIAD; Arog; Novartis
George D. Demetri
Consultant or Advisory Role - ARIAD; Blueprint Medicines; Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals; Merck; Merrimack; N-of-One (U); Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; Champions Biotechnology; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - GlaxoSmithKline; Johnson & Johnson (U); Merck (U)